Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time, with a favorable safety profile, in the open-label extension trial.

Lecanemab and donanemab effects lasting over three years, new treatments, trials of home injections and blood tests for ...

Lecanemab, the disease-modifying drug which can slow down the progression of Alzheimer’s disease, is set to be one of the most sought-after medications in the country after UK regulators ...

What the science says about lecanemab On Friday, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee met to discuss the results from a confirmatory Phase 3 study on ...

The FDA’s accelerated approval of lecanemab was expected, said Dr. Richard Isaacson, director of the Alzheimer’s Prevention Clinic in the Center for Brain Health at Florida Atlantic University ...

Lecanemab and Aduhelm are part of a class of drugs called monoclonal antibodies, and the agency that oversees Medicare has said it will only pay for this type of Alzheimer’s drug for patients ...

Lecanemab's price may pose another barrier, even with insurance coverage. The drug's maker, Eisai, expects the medicine alone to cost $26,500 a year. Diagnostic and follow-up tests will add to that.

A health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese ...

But lecanemab’s quest for approval has been shadowed by the previous approval of another Alzheimer’s drug to get accelerated approval: aducanemab, sold as Aduhelm. During aducanemab’s ...